Bromazolam in impaired driving investigations
Journal of Analytical Toxicology · 15.11.2024 · 48 (9) · 653-658
DOI: 10.1093/jat/bkae074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Analytical Toxicology, online erschienen am 28.08.2024. Verfasst von Jolene J Bierly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Toxicological Services, NMS Labs, Horsham, PA 19044, USA. Hauptthemen laut MEDLINE: Substance Abuse Detection, Driving Under the Influence, Automobile Driving, Tandem Mass Spectrometry. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
The designer benzodiazepine bromazolam is increasingly encountered in forensic casework, including impaired driving investigations. A series of suspected impaired driving cases that tested positive for bromazolam are described herein along with information about driving performance, driver appearance, and observed behavior. Bromazolam was indicated in casework either through screening by liquid chromatography–time of flight mass spectrometry (LC–TOF-MS) and/or a positive benzodiazepine immunoassay screen. Blood samples were forwarded for quantitative confirmatory analysis using a liquid chromatography–tandem mass spectrometry (LC–MS–MS) method with a reporting limit of 2.0 ng/mL. Bromazolam was reported in 98 impaired driving cases from samples reported between January 2021 and December 2023, with the earliest detection from September 2020. Mean and median blood concentrations were 125 ± 145 and 84 ng/mL respectively, with a range of 4.2–990 ng/mL. Additional positive findings were reported in almost all cases, with the highest result (990 ng/mL) being the only case in which bromazolam was the only finding. Fentanyl was the most frequent drug found in combination with bromazolam. Driving behaviors reported in these cases included erratic driving, errors in Standardized Field Sobriety Tests, and symptoms consistent with central nervous system depressants, including slurred speech, incoordination, and lethargic behavior. Based on its prevalence and demonstrated impairing effects, bromazolam should be included in the scope of impaired driving testing as long as it continues to be prevalent in the drug supply.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Toxicological Services, NMS Labs, Horsham, PA 19044, USA.
- Center for Forensic Science Research and Education, Horsham, PA 19044, USA.
ORCID-Profile: Jolene J Bierly, Donna M Papsun, Barry K Logan
Zitieren
APA
Bierly, J. J., Papsun, D. M., & Logan, B. K. (2024). Bromazolam in impaired driving investigations. Journal of Analytical Toxicology, 48(9), 653-658. https://doi.org/10.1093/jat/bkae074
Vancouver
Bierly JJ, Papsun DM, Logan BK. Bromazolam in impaired driving investigations. Journal of Analytical Toxicology. 2024;48(9):653-658. doi:10.1093/jat/bkae074
BibTeX
@article{Bierly2024,
author = {Bierly, Jolene J and Papsun, Donna M and Logan, Barry K},
title = {Bromazolam in impaired driving investigations},
journal = {Journal of Analytical Toxicology},
year = {2024},
volume = {48},
number = {9},
pages = {653--658},
doi = {10.1093/jat/bkae074}
}
EUVIMED